课题基金 / 基金详情

STAPHEX II: Dissecting Staphylococcus aureus macrophage exit

STAPHEX II: Dissecting Staphylococcus aureus macrophage exit
STAPHEX II:解剖金黄色葡萄球菌巨噬细胞出口
批准号:
446507619
负责人:
Professor Dr. Alexander Weber, Ph.D.
金额:
$0.0万
依托单位:
依托单位国家:
德国
项目类别:
Priority Programmes
财政年份:
--
资助国家:
德国
项目状态:
未结题
起止时间:

项目摘要

项目成果

Professor Dr. Alexander Weber, Ph.D.的其他基金

相似基金

相关文献

中文摘要
翻译
鼻腔携带金黄色葡萄球菌是严重侵袭性感染的主要危险因素。即使经过最先进的抗生素治疗,临床感染复发也并不罕见,这表明细菌可能隐藏在细胞内。最近在小鼠实验模型中的研究表明,金黄色葡萄球菌在肝脏或腹膜巨噬细胞的细胞内储存库中的持续存在对脓毒症的病理发展至关重要。在慢性感染(如骨髓炎)期间,金黄色葡萄球菌也可在细胞内持续较长时间。在分子和细胞水平上,金黄色葡萄球菌的传播和宿主细胞的退出或持久性尚不清楚。金黄色葡萄球菌进入血液后,容易被多种类型的吞噬细胞吞噬,如巨噬细胞。然而,这种病原体能够在人类巨噬细胞内存活并从中逃逸。我们之前可以证明酚可溶性调节素(psm)和人类特异性双组分杀白细胞素LukAB和/或PVL对这一过程至关重要。psm可以不依赖受体裂解细胞,介导金黄色葡萄球菌从吞噬体逃逸到细胞质中,并在小鼠和人体内发挥作用。相反,LukAB和PVL是高度依赖受体的,并且仅限于人类,这阻碍了在传统小鼠模型中对这些毒素的分析。我们的数据表明,LukAB以非常规的方式促进人巨噬细胞逃逸和细胞死亡:尽管NLRP3炎性体被激活导致il -1 β释放,但不涉及焦亡或凋亡;相反,MLKL/坏死下垂特征被激活,但不足以导致毒素依赖性细胞死亡和退出。使用新的基因标记的细菌和细胞系可以监测出口的特征,并可能涉及通过efferocytosis直接传播到未感染的巨噬细胞。与SPP的主要目标非常一致,这里将解决三个由此产生的问题:1)ExitStaph中LukAB诱导的哪些机制与MLKL协同作用或单独作用?宿主细胞是如何重新编程的?2)来自内部的LukAB的活性是否严格依赖于经典的CD11b结合和/或信号传导,或涉及其他细菌和/或宿主因子?3)细胞间的传播是否涉及细胞中游离细菌的真正退出和释放,以供随后的再感染,还是涉及细菌与细胞碎片的结合摄取(efferocytosis)?细菌转移的两种途径有什么不同?通过结合我们在分子和细胞免疫细胞信号传导(Weber)以及金黄色葡萄球菌生理学和基因工程(Wolz)方面的专业知识,我们将确定驱动细胞死亡或金黄色葡萄球菌持久性的关键决定因素。了解金黄色葡萄球菌逃避细胞内杀伤、存活和逃逸的机制,可以为使用新的抗感染治疗方法更好地分类和治疗临床金黄色葡萄球菌表型铺平道路。
英文摘要
Nasal carriage of Staphylococcus aureus is a major risk factor for severe and invasive infections. Clinical infection relapse even after state-of-the-art antibiotic therapy is not uncommon, suggesting that bacteria may hide inside cells. Recent studies in murine experimental models indicate that S. aureus persistence in intracellular reservoirs in macrophages in the liver or the peritoneum is critical for the pathology of sepsis development. During chronic infections such as osteomyelitis, S. aureus may also persist within cells for prolonged time. On a molecular and cellular level S. aureus dissemination and host cell exit or persistence are not well understood. After entering the bloodstream, S. aureus is readily phagocytosed by multiple types of phagocytes, e.g. macrophages. However, the pathogen is able to survive within human macrophages and escape from within. We could previously show that phenol soluble modulins (PSMs) and human-specific two component leukocidins LukAB and/or PVL are crucial for this process. PSMs can lyse cells receptor-independently, mediate the escape of S. aureus from phagosomes into the cytosol and function in mouse and humans. Conversely, LukAB and PVL are highly receptor dependent and restricted to humans, hampering analysis of these toxins in conventional mouse models. Our data indicate that LukAB promotes human macrophage escape and cell death in a non-conventional manner: although the NLRP3 inflammasome is activated resulting in IL-1beta release, pyroptosis or apoptosis are not involved; rather MLKL/necroptosis features are activated but are not sufficient for toxin-dependent cell death and exit. Using novel genetically labeled bacteria and cell lines features of exit can be monitored and may involve direct spread to uninfected macrophages by efferocytosis. In good agreement with the SPP’s key aims three resulting questions will be addressed here: 1) Which mechanisms induced by LukAB in ExitStaph synergize with MLKL or act independently? How is the host cell reprogrammed? 2) Is the activity of LukAB from within strictly dependent on classical CD11b binding and/or signaling or involves other bacterial and/or host factors? 3) Does cell-to-cell spread involve bona fide exit and release of free bacteria from cells for subsequent re-infection or does it rather entail uptake of bacteria in combination with cellular debris (efferocytosis)? What are the differences of the two alternative routes of bacterial transfer? By combining our expertise in the molecular and cellular immune cell signaling (Weber) and S. aureus physiology and genetic engineering (Wolz), we will define the key determinants driving cell death or S. aureus persistence. Understanding the mechanisms employed by S. aureus to evade intracellular killing, survive and escape could pave the way for better classification and treatment of clinical S. aureus phenotypes using novel anti-infective treatment approaches.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ImMiGeNe - Interplay of immune parameters, microbiota and host genetics during childhood stem cell transplantation
  • 批准号:
    433115696
  • 项目类别:
    Research Grants
  • 资助金额:
    $0.0万
  • 财政年份:
    2020
  • 负责人:
    Professor Dr. Alexander Weber, Ph.D.
  • 依托单位:
Molecular Role of Bruton’s Tyrosine Kinase (BTK) in NLRP3 Inflammasome Activation
  • 批准号:
    414795436
  • 项目类别:
    Research Grants
  • 资助金额:
    $0.0万
  • 财政年份:
    2019
  • 负责人:
    Professor Dr. Alexander Weber, Ph.D.
  • 依托单位:
Molecular Sensing of Chitin by Toll-like Receptors
  • 批准号:
    388534740
  • 项目类别:
    Research Grants
  • 资助金额:
    $0.0万
  • 财政年份:
    2018
  • 负责人:
    Professor Dr. Alexander Weber, Ph.D.
  • 依托单位:
Structure-function relationships of Toll-like receptors, key mediators of antiviral innate immunity, in Human Papillomavirus 16 infection and cervical cancer
  • 批准号:
    23262953
  • 项目类别:
    Independent Junior Research Groups
  • 资助金额:
    $0.0万
  • 财政年份:
    2006
  • 负责人:
    Professor Dr. Alexander Weber, Ph.D.
  • 依托单位:
国内基金
海外基金
基于生境成像与深度学习联合临床特征构建II型卵巢癌术前淋巴结转移预测模型的研究
鸡软骨非变性II型胶原高效制备和靶向递送的关键技术开发与应用示范
青蒿琥酯协同TROP2/线粒体级联靶向的NIR-II多模态诊疗用于晚期TNBC精准诊断与治疗的机制研究
  • 批准号:
    2026JJ30126
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    杨沙
  • 依托单位:
肿瘤侵袭边界SERPINA3+MHC-II+胶质细胞驱动GBM免疫抑制的机制研究
  • 批准号:
    82674293
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    武明花
  • 依托单位: